Company Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States.

The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.

The company was incorporated in 2012 and is headquartered in San Carlos, California.

Allakos Inc.

Country	United States
Founded	2012
IPO Date	Jul 19, 2018
Industry	Biotechnology
Sector	Healthcare
Employees	131
CEO	Dr. Robert Alexander Ph.D.

Contact Details

Address: 825 Industrial Road, Suite 500 San Carlos, California 94070 United States
Phone	650-597-5002
Website	allakos.com

Stock Details

Ticker Symbol	ALLK
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001564824
CUSIP Number	01671P100
ISIN Number	US01671P1003
Employer ID	45-4798831
SIC Code	2834

Key Executives

Name	Position
Dr. Robert Alexander Ph.D.	Chief Executive Officer and Director
Dr. Adam L. Tomasi Ph.D.	President
Baird Radford III	Chief Financial Officer
Mary Cromwell Ph.D.	Chief Technical Officer
Dr. Chin Lee M.D., M.P.H.	Chief Medical Officer
Alan Chang	Director of Medical Affairs and Data Analytics

Latest SEC Filings

Date	Type	Title
Jul 8, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Jun 28, 2024	144	Filing
Jun 25, 2024	8-K	Current Report
Jun 25, 2024	8-K	Current Report
Jun 7, 2024	144	Filing
Jun 6, 2024	144	Filing
Jun 4, 2024	144	Filing
May 28, 2024	8-K	Current Report
May 28, 2024	8-K	Current Report
May 9, 2024	10-Q	Quarterly Report

View All SEC Filings